• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Waters Expands Alliance iS Bio HPLC Product Line with Photodiode Array Detector to Enhance Spectral Insights for Biopharma Development & QC

    4/1/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email

    News Summary

    • Boosts out-of-the-box sensitivity by up to 80 times with MaxPeakTM Premier columns.1
    • Delivers over threefold improvements in day-to-day reproducibility2 and decreases carryover by up to two orders of magnitude.3
    • Reduces common user errors by up to 40%.4

    MILFORD, Mass., April 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the expansion of the Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA) detection, advancing the capabilities of the next-generation intelligent HPLC platform designed for development and Quality Control (QC) laboratories.

    The new Waters Alliance iS Bio HPLC System with integrated PDA Detector combines advanced bioseparation technology with built-in instrument intelligence to enhance flexibility, operational efficiency, performance, and ease of use in biopharma quality control (QC) laboratories

    Enhances out-of-the-box sensitivity by up to 80 times compared to traditional systems and columns.

    "The addition of the Alliance iS Bio HPLC System with PDA detection allows biopharmaceutical laboratories to perform enhanced spectral analysis, including impurity detection, peak purity analysis, multi-wavelength detection, and method validation, to deliver safe and effective products," said Fraser McLeod, Vice President, General Manager, QA/QC, at Waters Corporation. "Built on the Alliance iS HPLC Platform, the system is designed to simplify the analysis of complex biopharmaceuticals in development and QC, reduce errors, and improve accuracy and operational efficiency."

    The Alliance iS HPLC Platform has been purposefully designed to simplify laboratory workflows by reducing the risk of out-of-specification results and the need for troubleshooting. Default system parameters provide over threefold improvement in day-to-day reproducibility2 and reduce carryover by up to two orders of magnitude,3 compared to other systems on the market. Additionally, with MaxPeak Premier columns, the Alliance iS Bio HPLC System enhances out-of-the-box sensitivity by up to 80 times compared to traditional systems and columns.1  

    Waters now offers four configurations of the Alliance iS HPLC Platform to support routine quantitative analysis and expanded spectral analysis of small and large molecules in development and QC. All configurations are controlled by the compliance-ready Waters EmpowerTM Chromatography Data System, which enables laboratories to collect, manage, and report chromatography test results. The platform also supports connectivity with laboratory information management systems (LIMS) to help high-volume QC labs manage operational risk, mitigate disruptions, and increase overall productivity.

    The Alliance iS HPLC Platform has earned the Accountability, Consistency, and Transparency (ACT) Ecolabels from My Green Lab, a nonprofit organization dedicated to building a global culture of sustainability in science. Notably, the product line was recognized for its sustainable manufacturing practices and innovative error-reducing design, underscoring the commitment of Waters to reducing the most significant environmental impacts.

    The Waters Alliance iS Bio HPLC System with PDA detection is available for order now.

    Additional Resources:

    • See detailed specifications and configurations: Waters Alliance iS Bio HPLC System
    • Watch the Alliance iS Bio HPLC System Video
    • Watch the Webinar Replay
    • Follow and connect with Waters LinkedIn, Twitter, and Facebook

    Waters, Alliance, MaxPeak, and Empower are trademarks of Waters Technologies Corporation.

    About Waters Corporation (www.waters.com)

    Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

    Contact:

    Janice Foley

    Senior Public Relations Manager, Corporate Communications

    Waters Corporation

    [email protected]

    Mobile: +1.617.823.5555

    1. Application Note: Mitigation of Non-Specific Adsorption During Column Conditioning for an Oligonucleotide HILIC Analysis | Waters. In a well-controlled experiment, oligonucleotides were analyzed with a HILIC application to compare method performance with stainless steel systems and columns with MaxPeak HPS solutions. Percent recovery was tracked for all possible configurations without system passivation and the system configuration with a MaxPeak HPS column and Alliance iS Bio System outperformed other configurations with 80x greater sensitivity than an all-stainless-steel configurations (Figure 10).

    2. Application Note: HPLC Autosampler Performance II: Improved Injection Precision of USP Methods With the Alliance™ iS HPLC System. In multiple well-controlled experiments with a range of analytes and diluents, injection precision was highest on the Alliance iS HPLC system compared to other HPLC systems on the market.



    3. Application Note: Improved chlorhexidine carryover performance using the Alliance iS HPLC System. In a well-controlled experiment, chlorhexidine carryover was measured to be 0.00055% on the Alliance iS HPLC System and up to 0.05% for other HPLC systems on the market.



    4. Based on Waters market research in 2022, surveying 56 global Pharma QC labs running >25 systems.



    Waters Corporation (PRNewsfoto/Waters Corporation)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/waters-expands-alliance-is-bio-hplc-product-line-with-photodiode-array-detector-to-enhance-spectral-insights-for-biopharma-development--qc-302416120.html

    SOURCE Waters Corporation

    Get the next $WAT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    10/8/2025$390.00Buy
    Rothschild & Co Redburn
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/8/2024$355.00 → $415.00Hold → Buy
    Jefferies
    More analyst ratings

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics

    Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3MILFORD, Mass., Oct. 13, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterization for the broadest range of mega-mass biomolecules central to next-ge

    10/13/25 8:05:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call

    MILFORD, Mass., Oct. 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2025 financial results conference call on Tuesday, November 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 2nd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety

    10/1/25 12:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation to Present at the Wells Fargo Healthcare Conference

    MILFORD, Mass., Aug. 26, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Thursday, September 4th, 2025, at 9:30 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences

    8/26/25 4:10:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    SEC Filings

    View All

    SEC Form 425 filed by Waters Corporation

    425 - WATERS CORP /DE/ (0001000697) (Subject)

    10/14/25 5:04:56 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 425 filed by Waters Corporation

    425 - WATERS CORP /DE/ (0001000697) (Subject)

    9/16/25 4:15:18 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 425 filed by Waters Corporation

    425 - WATERS CORP /DE/ (0001000697) (Subject)

    9/4/25 4:52:39 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rothschild & Co Redburn initiated coverage on Waters with a new price target

    Rothschild & Co Redburn initiated coverage of Waters with a rating of Buy and set a new price target of $390.00

    10/8/25 8:37:34 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00

    3/31/25 7:57:55 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously

    3/26/25 7:47:54 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/29/24 11:23:35 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Knight Heather was granted 78 shares, increasing direct ownership by 11% to 759 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    10/2/25 4:16:38 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Jiang Wei was granted 73 shares, increasing direct ownership by 3% to 2,551 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    10/2/25 4:15:15 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Knight Heather was granted 68 shares, increasing direct ownership by 11% to 681 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    7/1/25 7:20:58 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Financials

    Live finance-specific insights

    View All

    Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call

    MILFORD, Mass., Oct. 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2025 financial results conference call on Tuesday, November 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 2nd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety

    10/1/25 12:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results

    Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currencyGAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customersRecurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growthIn constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expectedRaising full-year 2025 constant currency sales growth guidance to +5.5% to

    8/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

    Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growthCreates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brandsAnticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five  Delivers a

    7/14/25 6:15:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

    MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

    5/21/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Heather Knight to Board of Directors

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Richard Fearon to Board of Directors

    Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,

    3/28/23 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/14/24 9:37:22 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/13/24 5:17:31 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials